Fundraising Fox
bioAffinity Technologies
NASDAQ: BIAFSan Anonio, US · Founded 2014 · Delaware corporation
Find your way into bioAffinity Technologies
Sign up to see every warm intro you have to bioAffinity Technologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the bioAffinity Technologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
bioAffinity Technologies develops noninvasive laboratory diagnostic tests that use flow cytometry and machine learning analysis to detect early-stage lung cancer and other lung diseases from sputum samples. The company's lead product, CyPath® Lung, is offered through its subsidiary PPLS, a CAP-accredited clinical laboratory, and serves physicians evaluating patients at high risk for lung cancer.
Founders & leadership
bioAffinity Technologies was founded in 2014 by Maria Zannes.
MZ
Maria ZannesFounder · Chief Executive Officer, President and Director at bioAffinity Technologies, Inc.Maria Zannes holds a B.A. in Journalism from the University of New Mexico and a J.D. from the University of Puget Sound; she brings over three decades of executive management experience across the medical, environmental, and energy sectors, including prior roles as founder of The Zannes Firm, President of the Energy Recovery Council, and project manager at Wheelabrator Technologies, and is licensed to practice law in New Mexico.
VR
Vivienne RebelChief Science and Medical Officer
TP
Timothy P. ZannesExecutive VP and Secretary
MD
Michael DoughertyChief Financial Officer2023–2024He has over 20 years of international finance experience, including roles involving financial planning, reporting, M&A, and work with PE-backed companies.
MH
Myron HolubiakNamed on SEC filing
BF
Barry FrankelNamed on SEC filing
Board
GR
Gary RubinBoard director
JP
Jamie PlattBoard director
PK
Peter KnightBoard director
SD
Stuart DiamondBoard director
RJ
Roby JoyceBoard director
Funding
SEC filings, press & company announcements$8.4M disclosed across 4 of 9 rounds · 2017–2026
- Undisclosed amountprivate placementAug 2026Source ↗
- Undisclosed amountBest-Efforts OfferingJun 2026Source ↗
▶$4MofferedOct 2024 · 5 investors · BiotechnologyRule 506(b)
▶$4MofferedOct 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stuart DiamondDirector
- Vivienne RebelExecutive Officer
- Xavier RevelesExecutive Officer
- James EdwardsExecutive Officer
- Robert AndersonDirector
- Maria ZannesExecutive Officer, Director
- Steven GirgentiExecutive Officer, Director
- Roby JoyceDirector
- Jamie PlattDirector
- Peter S. KnightDirector
- Gary RubinDirector
- Timothy P. ZannesExecutive Officer
- Offering amount
- $4M
- Sales commissions
- $213K
- Placement agents
- Wallachbeth Capital LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$450KraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
▶$450KraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary RubinDirector
- Maria ZannesExecutive Officer, Director
- Roby JoyceDirector
- Robert A. AndersonDirector
- Jamie PlattDirector
- Xavier RevelesExecutive Officer
- Stuart DiamondDirector
- Michael DoughertyExecutive Officer
- Peter KnightDirector
- Timothy P. ZannesExecutive Officer
- Vivienne RebelExecutive Officer
- Steven GirgentiDirector
- Offering amount
- $450K
- Amount sold
- $450K
- Sales commissions
- $36K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedAug 2024 · 3 investors · BiotechnologyRule 506(b)
▶$1.3MraisedAug 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vivienne RebelExecutive Officer
- Gary RubinDirector
- Xavier RevelesExecutive Officer, Director
- Jamie PlattDirector
- Maria ZannesExecutive Officer, Director
- Peter KnightDirector
- Stuart DiamondDirector
- Roby JoyceDirector
- Robert A. AndersonDirector
- Steven GirgentiDirector
- Timothy P. ZannesExecutive Officer
- Michael DoughertyExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Sales commissions
- $104.2K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedMar 2024 · 3 investors · BiotechnologyRule 506(b)
▶$2.6MraisedMar 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roby JoyceDirector
- Maria ZannesExecutive Officer, Director
- Vivienne RebelExecutive Officer
- Michael DoughertyExecutive Officer
- Jamie PlattDirector
- Timothy P. ZannesExecutive Officer
- Steven GirgentiExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Minimum investment
- $2.6M
- Sales commissions
- $225K
- Placement agents
- WallachBeth Capital LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJul 2017 · 39 investors · BiotechnologyRule 506(b)
▶$4MraisedJul 2017 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Myron HolubiakDirector
- Barry FrankelDirector
- Steven GirgentiDirector
- Maria ZannesExecutive Officer, Director
- Robert AndersonDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$9.1Mvaluation at IPOMay 2025 · $0.32/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 3
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as bioAffinity Technologies.
Frequently asked questions
- What does bioAffinity Technologies do?
- bioAffinity Technologies develops noninvasive laboratory diagnostic tests that use flow cytometry and machine learning analysis to detect early-stage lung cancer and other lung diseases from sputum samples. The company's lead product, CyPath® Lung, is offered through its subsidiary PPLS, a CAP-accredited clinical laboratory, and serves physicians evaluating patients at high risk for lung cancer.
- Who founded bioAffinity Technologies?
- bioAffinity Technologies was founded by Maria Zannes in 2014.
- How much funding has bioAffinity Technologies raised?
- bioAffinity Technologies has disclosed $8.4M raised across 4 of its 9 known rounds.
- Where is bioAffinity Technologies headquartered?
- bioAffinity Technologies is headquartered in San Anonio, US.